Cell Type- and Developmental Stage-specific Activation of NF-kappa B by fMet-Leu-Phe in Myeloid Cells*

(Received for publication, November 22, 1996, and in revised form, January 6, 1997)

Darren D. Browning , Zhixing K. Pan , Eric R. Prossnitz and Richard D. Ye §

From the Department of Immunology, The Scripps Research Institute, La Jolla, California 92037

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgment
REFERENCES


ABSTRACT

Chemoattractants induce a variety of phagocytic functions including transendothelial migration, degranulation, and the generation of superoxide anions. We report here that the prototypic chemotactic peptide fMet-Leu-Phe (fMLF) stimulates the activation of nuclear factor-kappa B (NF-kappa B), a transcription factor that is central to the regulation of proinflammatory immediate-early gene expression. In freshly prepared peripheral blood mononuclear cells, fMLF (1-100 nM) induced a kappa B binding activity that was receptor-dependent and involved the p50 and p65 subunits of the NF-kappa B/Rel family of proteins. The activation of NF-kappa B by fMLF appeared to be cell-specific and different from the activation of NF-kappa B by tumor necrosis factor-alpha (TNFalpha ). Neutrophil preparations that responded to fMLF, TNFalpha , and lipopolysaccharides with interleukin-8 secretion did not show NF-kappa B activation, whereas N-formyl peptide receptor (FPR)-transfected HL-60 cells were responsive to TNFalpha but not fMLF for NF-kappa B activation. Differentiation of FPR-transfected HL-60 cells with dimethyl sulfoxide for 3-5 days conferred the capability of the cells to activate NF-kappa B in response to fMLF without a significant increase in the amount of FPR. These results identify NF-kappa B as a transcription factor that can be activated by the prototypic chemotactic peptide and demonstrate that this function is both highly regulated and dependent on signaling components specifically expressed during myeloid differentiation.


INTRODUCTION

The coordinated regulation of gene expression by phagocytic leukocytes is generally considered to be essential to the early inflammatory response in humans. The production of cytokines, chemokines, cell-surface receptors/adhesion proteins, and other molecules by activated monocytes, macrophages, and neutrophils can serve to orchestrate immune cell development and is essential to host defense against invading microorganisms. The regulation of gene expression in these cells is governed by the activities of transcription factors such as nuclear factor-kappa B (NF-kappa B),1 NF-IL-6, and AP-1, which are themselves regulated by external stimuli. NF-kappa B is of paramount importance to immune cell function owing to its ability to activate the transcription of many proinflammatory immediate-early genes (1, 2). NF-kappa B, which has been studied in great detail and shown to be dimeric in structure, is composed of members of the Rel family of transcriptional activators. In dormant cells NF-kappa B is normally complexed with a member of the Ikappa B proteins, which localizes the transcription factor to the cytosol in an inactive state (3). Stimulation of the cells with ligands such as lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNFalpha ), and IL-1beta results in rapid dissociation of Ikappa B and subsequent entry of the active NF-kappa B to the nucleus where it can interact with DNA. Although the signaling mechanisms leading to activation of NF-kappa B are not completely understood, it is widely believed that phosphorylation and degradation of Ikappa B is pivotal to this process (4-6).

More recent studies have demonstrated activation of NF-kappa B by G protein-coupled receptors (7-10). The lipid-derived chemoattractants platelet-activating factor (PAF) and leukotriene B4 (LTB4) can activate NF-kappa B in monocytes (9, 11, 12), and in transfected cell lines expressing the PAF receptor (10). Furthermore, this activation of NF-kappa B in monocytes results in the transcriptional activation of genes encoding cytokines and growth factors (9, 12). The ability of the lipid-derived chemoattractants to modulate gene expression through NF-kappa B reflects a potentially novel function of leukocyte chemoattractants in the inflammatory process. However, the scope of G protein-mediated NF-kappa B activation in leukocytes and its downstream signaling components remain to be determined.

N-Formylated peptides that may be released from invasive bacteria have been one of the most extensively studied chemoattractants. Much work has focused upon structural and functional analyses of the heptahelical cell-surface receptor for these peptides using the prototypic agonist N-formyl-methionyl-leucyl-phenylalanine (fMLF). Stimulation of monocytes and neutrophils with fMLF induces cellular functions including directed cell movement, phagocytosis, and the generation of reactive oxygen intermediates (13). A variety of signaling pathways leading from receptor activation of pertussis toxin-sensitive G proteins that contribute to the regulation of these processes have been documented (14). More recent studies have demonstrated that peptide chemoattractants such as fMLF and C5a can stimulate cytokine secretion by monocytes, neutrophils and eosinophils (15, 16). With eosinophils, the involvement of the transcription factor NF-kappa B was suggested although no direct evidence for NF-kappa B activation was provided (16). We investigated the ability of fMLF to activate NF-kappa B in myeloid cells and demonstrate here that this peptide chemoattractant can activate NF-kappa B in human monocytes but not in neutrophils or in the promyelocytic HL-60 cells. Differentiation of HL-60 cells with dimethyl sulfoxide (Me2SO) resulted in the acquisition of fMLF-stimulated activation of NF-kappa B that was independent of receptor up-regulation. In addition, transfected HL-60 cells expressing functional FPR were responsive to TNFalpha but not to fMLF for NF-kappa B activation, suggesting the involvement of separable signaling pathways leading to transcription factor activation. These findings indicate that activation of NF-kappa B may be a general function of chemoattractants but is limited to specific classes of terminally differentiated myeloid cells. Furthermore, this work highlights the utility of HL-60 cells as a model for a more detailed investigation of the signaling mechanisms leading to NF-kappa B activation by different ligands.


EXPERIMENTAL PROCEDURES

Materials

LPS isolated from Salmonella minnesota Re595 was a gift from R. Ulevitch (Scripps Research Institute). Recombinant murine TNFalpha was kindly provided by V. Kravchencko (Scripps Research Institute). The recombinant TNFalpha contains less than 0.277 ng/mg LPS as measured by the Limulus amebocyte lysate assay (Cap Cod Associates, Woods Hole, MA). Pyrrolidinedithiocarbamate (PDTC), purchased from Sigma, was kept as a 1 mM stock in H2O and was added to cultures directly. FITC-fMLF (Molecular Probes, Eugene, OR) and unlabeled fMLF (Sigma), were diluted with posphate-buffered saline from concentrated stocks maintained at -20 °C in Me2SO. A double-stranded oligonucleotide probe containing a decameric kappa B sequence (underlined) 5'-AGTTGAG<UNL>GGGACTTTCC</UNL>CAGG-3' was labeled using polynucleotide T4-kinase (Life Technologies, Inc.) and [gamma -32P]ATP (10 mCi/ml, Amersham Corp.). Rabbit polyclonal antibodies against a panel of NF-kappa B/Rel family of proteins were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-CD14 monoclonal antibody was from Coulter Immunology (Miami, FL), and phycoerythrin conjugated goat anti-mouse IgG was purchased from Sigma. Detection of IL-8 in culture supernatants was carried out using a commercially available enzyme-linked immunosorbent assay kit according to the procedures suggested by the manufacturer (Biosource International, Camarillo, CA).

Preparation of Cells

Human peripheral blood leukocytes were fractionated using Percoll based on the method of Ulmer and Flad (17). Briefly, blood was collected from healthy donors using acid citrate buffer containing 2% dextrose as an anticoagulant. Erythrocytes were removed by sedimentation with 6% hetastarch (Baxter). Peripheral blood mononuclear cells (PBMC) and neutrophils in the supernatant were further separated by centrifugation at 450 × g at 10 °C for 40 min through Percoll step gradients (70 and 55%). Viability of cells in a routine preparation was approximately 98% as determined by trypan blue exclusion. Following a wash in fresh RPMI 1640 medium (serum-free), cells (5 × 106) were stimulated with various ligands in 1.5-ml microcentrifuge tubes at 37 °C.

PBMCs prepared from several healthy donors were found to contain three populations of cells as identified by flow cytometry on forward and side scatter dot plots: platelets, lymphocytes and monocytes (Fig. 1). Using CD14 as a cell-surface marker for the monocytes, we observed that only these cells, but not platelets or lymphocytes, express the FPR as detected by FITC-fMLF direct binding (Fig. 1). Thus, PBMC was used without further fractionation, and any responses to fMLF could be attributed to binding and stimulation of monocytes in these preparations.


Fig. 1. Expression of the FPR in monocytes but not lymphocytes. Freshly prepared PBMC were analyzed by flow cytometry using FITC-fMLF (FL1) and phycoerythrin-conjugated anti-CD14 (FL2). The unlabeled dot plot (upper left) indicates three groups of cells: platelets (close to the origin), lymphocytes (shaded gray), and monocytes (shaded black). Other panels show staining with FITC-fMLF alone (upper right), phycoerythrin-anti-CD14 alone (lower left), and both FITC-fMLF and anti-CD14 (lower right). Similar results were obtained with three other PBMC preparations.
[View Larger Version of this Image (49K GIF file)]


The transfection of HL-60 cells with the FPR has been detailed elsewhere (18). Both transfected and untransfected HL-60 cells were maintained at 37 °C with 5% CO2 in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES (pH 7.0), penicillin (100 IU/ml), and streptomycin (50 mg/ml). HL-60 cells (5 × 105 cells/ml) were differentiated with Me2SO (1.3% v/v) over a period of 5 days, and the expression of the FPR was determined as described below.

Cell Staining and Flow Cytometry

All flow cytometry measurements were performed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). Determinations of fMLF receptor (FPR) expression were made by incubating cells (105) on ice for 10 min followed by the addition of FITC-conjugated fMLF (10 nM) for an additional 10 min. Quantitation of receptor expression on the whole cells was accomplished by relating the binding of saturating concentrations of [3H]fMLF to the fluorescence detected by flow cytometry. Subsequent receptor quantities were then determined by converting mean fluorescence by flow cytometry to receptor number. To identify monocytes in mononuclear fractions of human blood, cells were prelabeled with anti-CD14 monoclonal antibody (1:200), washed in posphate-buffered saline, and then incubated with phycoerythrin-conjugated goat anti-mouse IgG (1:500). All incubations were done on ice for 60 min; the cells were washed twice in posphate-buffered saline between each incubation and prior to flow cytometry analysis.

Electrophoretic Mobility Shift Assays

Following appropriate treatment of cells, nuclear extracts were prepared using the method of Dignam et al.(19) with minor modifications as detailed elsewhere (10). Prior to separation of DNA·protein complexes, binding reactions were initiated by adding 1 µl of (approximately 1 × 106 cpm) labeled kappa B probe to a reaction mixture which had been preincubated for 10 min at room temperature. The mixture contained 2-5 µg of nuclear extract in binding buffer (2.5 mM HEPES, pH 7.8, 2.5 mM MgCl2, 25 mM KCl, 0.25 mM dithiothreitol, 0.2 µg/ml poly(dI-dC), 50 µg/ml sonicated salmon sperm DNA, and 5% glycerol). After an additional 10 min at room temperature mixtures were loaded onto pre-electrophoresed (60 min) 6% acrylamide gels and run at 100 V using a 50 mM Tris borate buffer containing 1 mM EDTA. After separation, gels were dried on Whatman DE81 paper and exposed to a phosphor imaging plate (Molecular Dynamics) or x-ray film if necessary. For supershift analysis, approximately 4 µl of antibodies (1 mg/ml) against NF-kappa B subunits were incubated with the binding mixtures for 15 min prior to the addition of radiolabeled probe.

Western Blotting and Immunodetection

Whole cell lysates were solubilized by dilution with 2 × polyacrylamide gel electrophoresis buffer and 20 µg of protein was separated on 10% denaturing SDS gels using the method of Laemmli (20). Protein profiles were then transferred to nitrocellulose membranes (Hybond ECL, Amersham Corp.) and blocked overnight at 4 °C in PTS buffer (10 mM phosphate buffer, pH 7.0, 0.05% Tween 20, 0.9% NaCl, and 0.025% NaN3) containing 3% bovine serum albumin. NF-kappa B subunits were detected on the blots by incubation for 1 h with a 1:1,000 dilution of either anti-p50 or anti-p65 rabbit polyclonal antibodies (Santa Cruz Biotechnology). After 3 washes in PTS containing 1% bovine serum albumin, blots were probed with 1:5,000 alkaline phosphatase-conjugated goat anti-rabbit IgG for 1 h. Following extensive washing, immunodetected proteins were visualized by incubation with alkaline phosphatase substrate (Sigma). Protein concentrations were determined using the BCA reagents (Pierce).


RESULTS

Recent studies have identified a G protein-coupled signaling pathway initiated by the LTB4 and PAF receptors that leads to the activation of NF-kappa B in human monocytes (9, 11, 12). Because monocytes express receptors for several other chemoattractants including fMLF, we examined whether fMLF could activate a similar pathway in these cells. The addition of a saturating concentration of fMLF (100 nM) to freshly isolated PBMC resulted in a rapid and transient activation of kappa B binding activity as measured by EMSA (Fig. 2A). The DNA·protein complexes were detected 30 min following addition of fMLF, peaked in amount after 60 min, and subsequently decreased to less than half of the maximum in 4 h. The extent of the induced DNA binding activity was dependent on the dose of fMLF as the response was detectable with nanomolar concentrations of fMLF and reached a maximum with 50 nM fMLF (not shown). The effectiveness of nanomolar concentrations of fMLF to induce kappa B binding activity suggested that it is a primary response to fMLF stimulation mediated by a high affinity receptor. This point was confirmed by blocking fMLF-induced kappa B binding activity with N-cinnamoyl-FLFLF (Fig. 2A), a newly identified fMLF receptor antagonist.2 Further fractionation of PBMC by centrifugation through additional Percoll gradients revealed that the purified monocytes displayed essentially the same kappa B binding activity in response to fMLF stimulation (data not shown).


Fig. 2. Identification of an fMLF-induced NF-kappa B response in PBMC. A, left panel, autoradiograph of EMSA indicating time-dependent induction of kappa B binding activity by fMLF (100 nM) in PBMC. Right panel, blockade of fMLF-induced kappa B binding by the FPR antagonist N-cinnamoyl-FLFLF (Antag.). Prior to nuclear extract preparation, the cells were treated for 60 min with fMLF (50 nM) in the absence or presence of the antagonist as indicated. C, control without fMLF stimulation. Arrows mark the DNA·protein complexes induced by fMLF. B, EMSA result showing the specificity of fMLF-induced kappa B binding activity. Left panel, competition by unlabeled kappa B oligonucleotide. The unlabeled kappa B probe, 0.5 and 5 pmol, was added to compete with 32P-labeled kappa B probe (approximately 0.05 pmol) for binding with the nuclear factor prior to EMSA. Right panel, the effect of PDTC on fMLF-induced NF-kappa B activation. The cells were incubated for 1 h with PDTC as indicated, followed by fMLF stimulation (50 nM, 1 h). C, control without fMLF stimulation. C, supershift analysis of NF-kappa B activated by fMLF in PBMC. Whereas no antibodies were added to the control lane, other lanes contained approximately 4 µg of antibodies specific for p50 and p65 (left panel), p52, c-Rel, and RelB (right panel) proteins as indicated above each lane. Arrows to the left indicate the deduced band composition. The above data are representative of three separate measurements, with similar results.
[View Larger Version of this Image (39K GIF file)]


Because NF-kappa B activation by fMLF has not been previously reported, we examined the specificity and composition of the resultant kappa B binding activity in the stimulated PBMC. Competition with unlabeled kappa B probe significantly reduced the major species identified on these gels thus indicating that the DNA binding activity was specific to the prototypic kappa B sequence (Fig. 2B). PDTC, an antioxidant inhibitor of NF-kappa B that functions by stabilization of the inhibitory protein Ikappa B (21), was found to block the appearance of the DNA·protein complexes in fMLF-stimulated cells (Fig. 2B). Gel mobility supershift with specific antibodies is widely used as supportive evidence for the identification of specific proteins in DNA·protein complexes detected by EMSA. In order to confirm the identity of the putative NF-kappa B species observed in fMLF-treated PBMC, nuclear extracts were preincubated with equal amounts of antibodies directed against well documented subunits of the NF-kappa B/Rel proteins. Gel retardation assays revealed upward shifting of the DNA·protein complexes only by antibodies against the p50 and p65 proteins (Fig. 2C), similar to the supershift pattern observed in other systems (22). These results indicate the presence of p50 and p65 subunits of the NF-kappa B/Rel protein family, possibly forming a p50/p50 homodimer and a p50/p65 heterodimer in the DNA·protein complex induced by fMLF. Preincubation of nuclear extracts with antibodies specific to p52, c-Rel, and RelB did not cause a supershift of the DNA·protein complex (Fig. 2C), but this experiment alone could not completely rule out the possibility that fMLF may activate other NF-kappa B/Rel proteins in these cells. Taken together, results derived from competition and supershift experiments confirmed fMLF induction of NF-kappa B activation in monocytes. The finding that PDTC inhibits the response suggested that fMLF-stimulated activation of NF-kappa B involves Ikappa B degradation similar to the responses reported for other inducers of NF-kappa B (4, 21).

It has been well established that monocytes are a major source of proinflammatory cytokines. More recently it has been reported that neutrophils also have transcriptional activity and can secrete cytokines including IL-1beta , IL-6, and IL-8 following activation with either cytokines such as TNFalpha or chemoattractants such as C5a and fMLF (15, 23). Since the expression of IL-1beta and IL-8 is regulated to a great extent by NF-kappa B at the level of transcription, we reasoned that stimulation with fMLF might activate NF-kappa B in these cells. This notion was examined by comparing the ability of PBMC and neutrophils to respond to fMLF as well as TNFalpha and LPS (Fig. 3A). The magnitude of the NF-kappa B response to fMLF in PBMC was similar to that of the better characterized inducers such as LPS and TNFalpha . Surprisingly, none of these agonists were able to induce detectable NF-kappa B activation in neutrophils stimulated for 1 h (Fig. 3A) or for several different time periods from 15 min to 2 h (data not shown).


Fig. 3. Absence of NF-kappa B activation in neutrophils. A, PBMC and neutrophils were incubated for 60 min with medium (Control), 100 ng/ml LPS, 40 ng/ml TNFalpha , or 100 nM fMLF (as indicated above each lane) followed by measurement of NF-kappa B activation by EMSA. Equal amounts of nuclear protein (5 µg) were loaded onto each lane. Blood cells prepared from 2 other donors gave similar results (not shown). The arrow marks the shifted DNA·protein complexes that were observed only in PBMC. B, the ability of fMLF, TNFalpha , and LPS to stimulate de novo IL-8 synthesis in neutrophils was determined using enzyme-linked immunosorbent assay as described under "Experimental Procedures." Approximately 107 cells/ml were stimulated with fMLF (100 nM), TNFalpha (40 ng/ml), or LPS (100 ng/ml) (hatched bars), with or without prior treatment of actinomycin D (5 µg/ml, 60 min) (solid bars). After 3 h, the cells were removed from the medium, and immunoreactive IL-8 in the supernatant was measured. The readings ± S.E. from three independent experiments are shown.
[View Larger Version of this Image (49K GIF file)]


In order to confirm that the neutrophil preparations were capable of de novo synthesis and secretion of cytokines, the cells were treated with fMLF, and the IL-8 protein secreted into the medium was measured. Stimulation of neutrophils with 100 nM fMLF caused a 4-5-fold increase in the levels of IL-8 protein secreted to the extracellular medium when compared with unstimulated cells (Fig. 3B). Furthermore, preincubation of cells with actinomycin D inhibited this increase suggesting that IL-8 protein synthesis in response to fMLF was dependent on transcription. The same neutrophil preparations were also responsive to TNFalpha and LPS, as both agonists stimulated IL-8 secretion by 8-10-fold, and this increase could be completely inhibited by actinomycin D (Fig. 3B). These results demonstrated that the neutrophils used in these experiments were not deleteriously altered by the fractionation process and responded similarly to TNFalpha , LPS, and fMLF.

Due to the lack of NF-kappa B activation in neutrophils following stimulation with several agonists, it was not clear whether NF-kappa B subunits were present in these cells. In order to clarify this issue, polyclonal antibodies against the p50 and p65 subunits of the NF-kappa B/Rel protein family were used to probe Western blots prepared from whole cell lysates of PBMC, neutrophils, and the promyelocytic cell line HL-60 (Fig. 4). The antibodies identified major species migrating at 50 and 65 kDa, respectively, in PBMC and HL-60 cells. In contrast, proteins migrating at parallel positions in lanes containing extracts from neutrophils were barely detectable. This finding suggested that the lack of NF-kappa B activation in neutrophils may be attributed to insufficient quantities of the p50 and p65 proteins in these cells.


Fig. 4. Expression of the p50 and p65 proteins in PBMC, neutrophils, and HL-60 cells. Whole cell lysates from PBMC, neutrophils, and HL-60 cells were analyzed for the presence of the p50 and p65 NF-kappa B proteins by Western blotting as detailed under "Experimental Procedures." Equal amounts of protein from each of the different cell types (indicated above the lanes) were loaded in each lane. The arrows indicate the position of 50- and 65-kDa proteins detected on the blots. Shown are representative data from at least three independent experiments.
[View Larger Version of this Image (86K GIF file)]


As a preliminary effort directed at the elucidation of the mechanism of NF-kappa B activation by fMLF, our attention focused on HL-60 cells as a potential model. The HL-60 cell is a promyelocytic cell line that can be induced to differentiate into both monocytic and granulocytic lineages (24). Treatment of HL-60 cells with Me2SO has been shown to induce granulocytic differentiation of the promyelocytic cells (25). Although other reagents such as phorbol myristate acetate and dibutyryl cyclic AMP can also initiate differentiation of HL-60 cells, they are capable of activating NF-kappa B (26) and therefore were not chosen for our studies. Following Me2SO (1.3% v/v) treatment, HL-60 cells attained the ability to respond to fMLF with NF-kappa B activation, while the undifferentiated cells were unresponsive to saturating concentrations of fMLF (Fig. 5A). As early as 3 days following Me2SO treatment, fMLF-dependent NF-kappa B activation could be detected, and this response was maximal in cells allowed to differentiate for 5 days. Me2SO treatment induced very little spontaneous NF-kappa B activation as the background remained low. Subunit analysis of fMLF-induced NF-kappa B composition by supershift assay indicated the presence of both p50 and p65 proteins similar to that observed in fMLF-stimulated monocytes (Fig. 5A; compare with Fig. 2C). Thus, Me2SO-differentiated HL-60 cells are fully capable of activating NF-kappa B in response to fMLF.


Fig. 5. Activation of NF-kappa B by fMLF and expression of the FPR in differentiated HL-60 cells. A, HL-60 cells were differentiated with Me2SO (1.3% v/v) for up to 5 days and tested for NF-kappa B activation by EMSA without or with fMLF stimulation (left two panels). Arrow denotes the shifted DNA·protein complexes. Right panel, the subunit composition of the DNA·protein complexes induced by fMLF in Me2SO-differentiated HL-60 cells was examined by supershift analysis as detailed under "Experimental Procedures." The Control lane contained the standard reaction mixture, whereas antibodies specific for the NF-kappa B subunits p50 and p65 were added to the other reaction mixtures prior to EMSA. Arrows identify the predicted subunit composition of the supershifted bands. Antibodies specific for p52, c-Rel, and RelB did not supershift the band (data not shown). Similar results were obtained in three independent experiments. B, histograms indicating the expression of FPR in HL-60 cells after Me2SO (1.3% v/v) differentiation in a 5-day period. Aliquots of the cells were taken on day 1, day 3, and day 5, stained with FITC-fMLF (10 nM), and analyzed by flow cytometry. Data shown are representative of three experiments.
[View Larger Version of this Image (38K GIF file)]


A number of granulocytic functions are acquired by HL-60 cells upon treatment with Me2SO, including chemotactic and phagocytic competence, inducible superoxide generation, and the increased expression of several chemoattractant receptors. As measured by FITC-fMLF binding, the expression of FPR on the cell surface increased dramatically in Me2SO-treated HL-60 cells after the 3rd day (Fig. 5B). In order to determine whether expression of FPR was the essential component responsible for fMLF-inducible NF-kappa B activation in differentiated cells, we tested FPR cDNA-transfected HL-60 cells with or without additional Me2SO treatment. As reported previously, the stably transfected HL-60 cells express functional FPR without differentiation (18). Stimulation of the transfected cells with fMLF induces several G protein-coupled functions including calcium mobilization and actin polymerization (18). However, in our experiments the transfected HL-60 cells did not exhibit significant levels of NF-kappa B activation when stimulated with fMLF (Fig. 6A). Similarly, only a weak NF-kappa B response was observed in HL-60 cells stably transfected to express the C5a receptor, which responded well to C5a with mobilization of Ca2+ (Fig. 6A). Notably, we observed that TNFalpha was able to stimulate a potent NF-kappa B activity in the transfected cells (Fig. 6A) as well as in untransfected HL-60 cells (see below), indicating that the signaling pathways utilized by TNFalpha for NF-kappa B activation were fully functional in these cells. This finding is in line with the Western blot data indicating that p50 and p65 subunits are present in the undifferentiated HL-60 cells (Fig. 4). These results suggest that TNFalpha stimulation of NF-kappa B activation utilizes signaling mechanisms that may be different from the ones employed by the G protein-coupled FPR in HL-60 cells, which apparently lack the response to fMLF despite the expression of the FPR by transfection.


Fig. 6. Responses of the transfected HL-60 cells to fMLF, C5a and TNFalpha . A, NF-kappa B activation in transfected HL-60 cells expressing the FPR and C5aR. The cells were either unstimulated (control) or stimulated with TNFalpha (40 ng/ml), fMLF (100 nM), or C5a (20 nM) for 1 h. Results from one of the two similar EMSA are shown, with the NF-kappa B and nonspecific (NS) species marked by arrows. B, Mobilization of calcium in the transfected cells in response to fMLF and C5a stimulation. Untransfected cells (top) did not show calcium mobilization when stimulated with these agonists (indicated by arrows). ATP (1 µM) was used as a positive control. The lower panels show calcium mobilization in response to fMLF and C5a in cells transfected with the respective receptor.
[View Larger Version of this Image (59K GIF file)]


The above data indicate that untransfected HL-60 cells lack not only the FPR but also a component that is necessary for efficient NF-kappa B activation in response to fMLF. This component may be acquired by differentiation of the cells with Me2SO, which at the same time also induces the expression of the FPR. To test this hypothesis, we treated the FPR-transfected HL-60 cells with Me2SO for 5 days and measured the capability of the differentiated cells to activate NF-kappa B in response to fMLF. As shown in Fig. 7, Me2SO-treated cells displayed marked NF-kappa B activation following fMLF stimulation while the background kappa B binding activity remained low. A similar result was obtained in C5a receptor-transfected HL-60 cells, which responded after Me2SO differentiation (data not shown). To examine whether Me2SO induced a significant increase in the FPR expression level that contributed to the NF-kappa B response to fMLF, the cells were subjected to flow cytometry analysis for quantitation of receptor expression. Without Me2SO treatment, FPR-transfected HL-60 cells expressed on average 148,000 receptors/cell based on mean fluorescence measurement against the FITC standard. Following differentiation with Me2SO for 5 days, the cells expressed on average 170,000 receptors/cell (n = 3) (Fig. 7). This is comparable with untransfected HL-60 cells, which expressed approximately 151,000 receptors/cells after a similar induction with Me2SO. Thus, the small increase (15%) in the numbers of FPR following Me2SO treatment cannot explain the marked gain in responsiveness to fMLF simulation.


Fig. 7. NF-kappa B activation in FPR-transfected HL-60 cells before and after Me2SO differentiation. Left panel, the FPR-transfected HL-60 cells were incubated for 1 h in the presence (+) or absence (-) of 100 nM fMLF followed by EMSA analysis of nuclear extracts for NF-kappa B activation. The undifferentiated cells are shown as control, whereas cells differentiated for 5 days with 1.3% Me2SO are labeled as DMSO. The arrow highlights the position of shifted DNA·protein complexes. One representative result from three experiments is shown. Right panel, expression of FPR in untransfected HL-60 (A), undifferentiated HL-60 transfected with the FPR cDNA (B), and transfected HL-60 cells following Me2SO differentiation for 5 days (C). The specific binding of FITC-fMLF (FL1) (10 nM) was confirmed by competition with unlabeled agonist (1 µM) using the transfected and differentiated HL-60 cells (D).
[View Larger Version of this Image (35K GIF file)]


In order to determine whether the increase in responsiveness of NF-kappa B to fMLF in HL-60 cells after differentiation was specific to the chemoattractant but not a result of a general increase in activable NF-kappa B, HL-60 cells at different stages following treatment with Me2SO were analyzed for p50 and p65 content by Western blot and for responsiveness to TNFalpha by EMSA (Fig. 8). In these experiments NF-kappa B activated by TNFalpha did not increase after differentiation but appeared to decrease in HL-60 cells treated with Me2SO for 3 and 5 days. The relative amounts of p50 and p65 proteins visible on Western blots also did not increase in HL-60 cells following Me2SO induction (Fig. 8). In fact, there appeared to be a slight decrease in the levels of the p65 protein. Thus, our data suggest the presence of a myeloid differentiation-associated factor that is necessary for fMLF- but not TNFalpha -stimulated NF-kappa B activation in HL-60 cells.


Fig. 8. Effect of Me2SO on HL-60 responsiveness to TNFalpha and the contents of p50 and p65 proteins. Left panel, HL-60 cells were differentiated with Me2SO (1.3% v/v) for up to 5 days and stimulated with TNFalpha (40 ng/ml). NF-kappa B activation was measured by EMSA. Right panel, the content of p50 and p65 proteins in whole cell lysates were determined by Western blotting using specific anti-p50 and -p65 antibodies after differentiation of the cells for 1, 3, and 5 days.
[View Larger Version of this Image (72K GIF file)]



DISCUSSION

Results from this study provide direct evidence for the activation of NF-kappa B by fMLF at concentrations comparable with those that stimulate other phagocyte cellular responses. This function of the well characterized chemoattractant may be of physiological relevance since chemoattractants are among the first and major activating factors that stimulate a migrating phagocyte. The physiological consequences of NF-kappa B activation as relevant to gene transcription were not the focus of this study. However, owing to both qualitative and quantitative similarities in the fMLF-induced NF-kappa B response to those elicited by either TNFalpha or LPS in monocytes, it is suggested that gene expression would result as has been well documented for these other ligands. Studies from this and other laboratories indicate that the chemoattractants LTB4 and PAF may also stimulate NF-kappa B-dependent gene expression suggesting that this might be a general function of leukocyte chemoattractants (9-12).

Leukocyte chemoattractants bind receptors with 7 transmembrane domains that signal by activating heterotrimeric G proteins. Proximal signaling events mediated by G proteins differ from those triggered by cytokines suggesting that chemoattractants might utilize signaling mechanisms different from those of TNFalpha and IL-1beta for activating NF-kappa B. It is predicted that both cytokine- and chemoattractant-initiated pathways converge at some point. As shown here TNFalpha could activate NF-kappa B in undifferentiated HL-60 whereas fMLF could not. The requirement of differentiation for fMLF responsiveness could thus be explained by the up-regulation of signaling components that function upstream of the point of convergence. It is also possible that chemoattractant-initiated pathways might involve one of the several signaling mechanisms utilized by TNFalpha for NF-kappa B activation; however, the slight decrease in TNFalpha -responsive NF-kappa B during HL-60 differentiation does not support this idea. Thus, results shown here indicate the presence of specific signaling components that may be unique to the G protein-mediated pathway(s) leading to NF-kappa B activation, reflecting a potentially novel mechanism for activating this transcription factor. Further study is necessary to identify the myeloid differentiation-associated factor and to determine whether myeloid differentiation is required for other chemoattractants to activate NF-kappa B.

Neutrophils are the primary effector cells found at sites of acute inflammation. In spite of the relative scarcity of ribosomes and endoplasmic reticulum, neutrophils are capable of mRNA synthesis and protein production (27). Neutrophils respond to a large number of proinflammatory stimuli including fMLF and other classical chemoattractants. It has been demonstrated that the chemoattractants fMLF, C5a, and LTB4 could synergize the effect of LPS on IL-8 synthesis by neutrophils, although the study did not demonstrate that these chemoattractants themselves could induce IL-8 production (28). Cassatella et al. (15) independently reported release of IL-8 by neutrophils after stimulation with fMLF alone. They observed de novo IL-8 protein synthesis, accompanied by an accumulation of the IL-8 mRNA. Furthermore, only nanomolar concentrations of fMLF were required for stimulation of IL-8 release, in agreement with our findings. These studies provided direct evidence for chemoattractant stimulation of cytokine production in neutrophils, but by themselves did not elucidate the transcriptional mechanisms for chemoattractant-induced cytokine production. Although NF-kappa B is a primary regulator of IL-8 gene expression in other cell types (29), the lack of kappa B binding activity in neutrophils as demonstrated by this work suggests that NF-kappa B is unlikely to play a major role in the transcription of cytokine genes in these terminally differentiated granulocytes. Thus, future investigations of gene transcription in neutrophils should be focused on the activation of other transcription factors such as NF-IL-6 and AP-1. Activation of the mitogen-activated protein kinases has been demonstrated by others to occur in neutrophils in response to fMLF (30-32). Since the activation of AP-1 can be regulated by the mitogen-activated protein kinase pathways (33), this transcription factor may have a role in neutrophil gene expression.

Recently Miyamasu et al. (16) reported that fMLF and C5a could cause secretion of cytokines by eosinophils. Although this response required pretreatment of the cells with cytochalasin B, it was dependent on transcription. Based on the finding that the antioxidant PDTC could block IL-8 generation, the authors postulated the involvement of NF-kappa B in fMLF- and C5a-stimulated response. However, no direct evidence was shown that supports NF-kappa B activation in the stimulated eosinophils. In light of our finding that neutrophils contain very little p50 and p65 and respond poorly to a number of agonists that induce NF-kappa B activation, additional work is necessary to determine whether eosinophils, a type of terminally differentiated granulocyte, differ from neutrophils in terms of NF-kappa B protein content and responsiveness to chemoattractants.

The finding that activation of NF-kappa B by fMLF in HL-60 cells requires granulocytic differentiation suggests that the final differentiation product more closely resembles a transitory state between promyelocyte and neutrophil. This notion is supported by the recent finding that certain granulocytic functions are enhanced in HL-60 cells when retinoic acid is added to the culture medium in the last day of differentiation with Me2SO (34). Furthermore, our results indicate that there is no increase in the content of the p50 protein and a visible decrease of the p65 protein in Me2SO-treated HL-60 cells undergoing granulocytic differentiation (Fig. 8). Thus, granulocytic differentiation may eventually result in the depletion of the NF-kappa B subunits as was observed here in neutrophils. Recent studies indicate a function for NF-kappa B in preventing apoptosis (35-37), raising the possibility that the loss of NF-kappa B and the commitment of neutrophils to cell death may not be just incidental. Whether chemoattractant-activated NF-kappa B occurs transiently during granulocytic differentiation in vivo is presently unknown, but the idea that NF-kappa B might serve a functional role during the differentiation of granulocytes is intriguing and warrants further study.


FOOTNOTES

*   Supported by National Institutes of Health Grants AI33503 (to R. D. Y.) and AI36357 (to E. R. P.), and it was conducted during the tenure of an Established Investigatorship Award from the American Heart Association (to R. D. Y.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   Recipient of a postdoctoral fellowship from the Arthritis Foundation.
§   To whom correspondence should be addressed: Dept. of Immunology, IMM-25, The Scripps Research Inst., 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-784-8583; Fax: 619-784-8483; E-mail: ye{at}scripps.edu.
1   The abbreviations used are: NF-kappa B, nuclear factor-kappa B; fMLF, N-formyl-Met-Leu-Phe; FPR, formyl peptide receptor; FITC, fluorescein isothiocyanate; PBMC, peripheral blood mononuclear cells; PAF, platelet-activating factor; LTB4, leukotriene B4; LPS, lipopolysaccharide; TNFalpha , tissue necrosis factor-alpha ; Me2SO, dimethyl sulfoxide; PDTC, pyrrolidinedithiocarbamate; EMSA, electrophoretic mobility shift assay; IL, interleukin; Ikappa B, inhibitory protein kappa B.
2   H. Solomon, unpublished observations.

Acknowledgment

We thank Wade Diehl for assistance in blood cell preparation.


REFERENCES

  1. Sen, R., and Baltimore, D. (1986) Cell 46, 705-716 [Medline] [Order article via Infotrieve]
  2. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 32, 141-179 [CrossRef]
  3. Baeuerle, P. A., and Baltimore, D. (1988) Science 242, 540-546 [Medline] [Order article via Infotrieve]
  4. Henkel, T., Machleidt, T., Alkalay, I., Krönke, M., Ben-Neriah, Y., and Baeuerle, P. A. (1993) Nature 365, 182-185 [CrossRef][Medline] [Order article via Infotrieve]
  5. Lin, Y. C., Brown, K., and Siebenlist, U. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 552-556 [Abstract]
  6. Finco, T. S., and Baldwin, A. S., Jr. (1995) Immunity 3, 263-272 [Medline] [Order article via Infotrieve]
  7. Mari, B., Imbert, V., Belhacene, N., Far, D., Peyron, J.-F., Pouyssegur, J., Van Obberghen-Schilling, E., Rossi, B., and Auberger, P. (1994) J. Biol. Chem. 269, 8517-8523 [Abstract/Free Full Text]
  8. Nakajima, T., Kitajima, I., Shin, H., Takasaki, I., Shigeta, K., Abeyama, K., Yamashita, Y., Tokioka, T., Soejima, Y., and Maruyama, I. (1994) Biochem. Biophys. Res. Commun. 204, 950-955 [CrossRef][Medline] [Order article via Infotrieve]
  9. Pan, Z., Kravchenko, V. V., and Ye, R. D. (1995) J. Biol. Chem. 270, 7787-7790 [Abstract/Free Full Text]
  10. Kravchenko, V. V., Pan, Z., Han, J., Herbert, J.-M., Ulevitch, R. J., and Ye, R. D. (1995) J. Biol. Chem. 270, 14928-14934 [Abstract/Free Full Text]
  11. Brach, M. A., de Vos, S., Arnold, C., Gruss, H.-J., Mertelsmann, R., and Herrmann, F. (1992) Eur. J. Immunol. 22, 2705-2711 [Medline] [Order article via Infotrieve]
  12. Weyrich, A. S., McIntyre, T. M., McEver, R. P., Prescott, S. M., and Zimmerman, G. A. (1995) J. Clin. Invest. 95, 2297-2303 [Medline] [Order article via Infotrieve]
  13. McPhail, L. C., and Harvath, L. (1993) in The Neutrophil (Abramson, J. S., and Wheeler, J. G., eds), pp. 63-107, IRL Press, Oxford
  14. Snyderman, R., and Uhing, R. (1992) in Inflammation: Basic Principles and Clinical Correlates (Gallin, J., Goldstein, I., and Snyderman, R., eds), 2nd Ed., pp. 421-439, Raven Press, New York
  15. Cassatella, M. A., Bazzoni, F., Ceska, M., Ferro, I., Baggiolini, M., and Berton, G. (1992) J. Immunol. 148, 3216-3220 [Abstract/Free Full Text]
  16. Miyamasu, M., Hirai, K., Takahashi, Y., Iida, M., Yamaguchi, M., Koshino, T., Takaishi, T., Morita, Y., Ohta, K., Kasahara, T., and Ito, K. (1995) J. Immunol. 154, 1339-1349 [Abstract/Free Full Text]
  17. Ulmer, A., and Flad, H. (1979) J. Immunol. 30, 1-10
  18. Prossnitz, E. R., Quehenberger, O., Cochrane, C. G., and Ye, R. D. (1993) J. Immunol. 151, 5704-5715 [Abstract/Free Full Text]
  19. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489 [Abstract]
  20. Laemmli, U. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  21. Schreck, R., Meier, B., Mannel, D., Droge, W., and Baeuerle, P. A. (1992) J. Exp. Med. 175, 1181-1194 [Abstract]
  22. Fujita, T., Nolan, G. P., Ghosh, S., and Baltimore, D. (1992) Genes Dev. 6, 775-787 [Abstract]
  23. Lloyd, A. R., and Oppenheim, J. J. (1992) Immunol. Today 13, 169-172 [CrossRef][Medline] [Order article via Infotrieve]
  24. Harris, P., and Ralph, P. (1995) J. Leukocyte Biol. 37, 407-422 [Abstract]
  25. Collins, S., Ruscetti, F., Gallagher, R., and Gallo, R. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2458-2462 [Abstract]
  26. Griffin, G., Leung, K., Folks, T., Kunkel, S., and Nabel, G. (1989) Nature 339, 70-73 [CrossRef][Medline] [Order article via Infotrieve]
  27. Jack, R. M., and Fearon, D. T. (1988) J. Immunol. 140, 4286-4293 [Abstract/Free Full Text]
  28. Strieter, R. M., Kasahara, K., Allen, R. M., Standiford, T. J., Rolf, W. M., Becker, F. S., Chensue, S. W., and Kunkel, S. L. (1992) Am. J. Pathol. 141, 397-407 [Abstract]
  29. Mukaida, N., Okamoto, S., Ishikawa, Y., and Matsushima, K. (1994) J. Leukocyte Biol. 56, 554-558 [Abstract]
  30. Grinstein, S., and Furuya, W. (1992) J. Biol. Chem. 267, 18122-18125 [Abstract/Free Full Text]
  31. Torres, M., Hall, F. L., and O'Neill, K. (1993) J. Immunol. 150, 1563-1578 [Abstract/Free Full Text]
  32. Worthen, G. S., Avdi, N., Buhl, A. M., Suzuki, N., and Johnson, G. L. (1994) J. Clin. Invest. 94, 815-823 [Medline] [Order article via Infotrieve]
  33. Karin, M. (1995) J. Biol. Chem. 270, 16483-16486 [Free Full Text]
  34. Iiri, T., Homma, Y., Ohoka, Y., Robishaw, J. D., Katada, T., and Bourne, H. R. (1995) J. Biol. Chem. 270, 5901-5908 [Abstract/Free Full Text]
  35. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784 [Abstract/Free Full Text]
  36. Wang, C. Y., Mayo, M. W., and Baldwin, A. S. J. (1996) Science 274, 784-787 [Abstract/Free Full Text]
  37. Van Antwerp, D., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.